Literature DB >> 6684595

Mechanism of cisplatin nephrotoxicity.

M W Weiner, C Jacobs.   

Abstract

cis-Diamminedichloroplatinum II (cisplatin) is widely used in cancer treatments. Renal dysfunction is the major toxic effect of this drug. Micropuncture studies suggest that cisplatin reduces single-nephron glomerular filtration rate (GFR) and causes a significant backleak of inulin across the renal tubule. Pathological alterations are localized to the S3 segment of the proximal tubule situated in the outer stripe of the outer medulla. Renal clearance studies in humans demonstrate that the free platinum clearance exceeds the GFR, which suggests that cisplatin or a platinum metabolite is actively secreted by the kidney. Studies with renal cortex slices indicate that platinum is accumulated by renal tissue against a concentration gradient. This uptake is blocked by metabolic inhibitors and the organic base triethanolamine. Heavy metals are thought to produce renal damage because of interaction with renal sulfhydryl (SH) groups. After cisplatin administration to rats, total renal SH groups decreased by 14% owing to a decrease of protein-bound SH groups. The greatest decline of SH groups occurred in the mitochondrial and cytosolic fractions. These fractions also had the highest platinum concentrations. These results suggest that the nephrotoxic effects of cisplatin may be related to depletion of SH groups, but a cause and effect relationship has not been definitively established.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6684595

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  18 in total

1.  Acute cisplatin nephrotoxicity in the rat. Evidence for impaired entry of sodium into proximal tubule cells.

Authors:  M J Field; T E Bostrom; F Seow; A Z Györy; D J Cockayne
Journal:  Pflugers Arch       Date:  1989-09       Impact factor: 3.657

Review 2.  Uptake carriers and oncology drug safety.

Authors:  Jason A Sprowl; Alex Sparreboom
Journal:  Drug Metab Dispos       Date:  2013-12-30       Impact factor: 3.922

3.  Theoretical study of the influence of the circadian rhythm of plasma protein binding on cisplatin area under the curve.

Authors:  B Hecquet; M Sucche
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 4.  An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.

Authors:  George J Dugbartey; Luke J Peppone; Inge A M de Graaf
Journal:  Toxicology       Date:  2016-10-04       Impact factor: 4.221

5.  Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity.

Authors:  A A Nanji; D J Stewart; N Z Mikhael
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  The influence of ageing on cisplatin pharmacokinetics in lung cancer patients with normal organ function.

Authors:  N Yamamoto; T Tamura; M Maeda; M Ando; T Shinkai; K Eguchi; Y Ohe; F Oshita; J Shiraishi; N Katsumata
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

Review 8.  WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.

Authors:  M Treskes; W J van der Vijgh
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Cisplatin overdose: toxicities and management.

Authors:  Roger Y Tsang; Turki Al-Fayea; Heather-Jane Au
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

10.  Clinical pharmacology of high-dose cisplatin.

Authors:  B J Corden; R L Fine; R F Ozols; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.